U
Abattis Bioceuticals Corp.
ATTBF
$0.00
$0.000.00%
D
Sell
5/1/2020Upgraded
Abattis Bioceuticals Corp. (ATTBF) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the growth index. Total revenue increased 79.48% from $95.5 to $171.4, and EBIT increased 35.09% from -$573.9 to -$372.5.
Abattis Bioceuticals Corp. (ATTBF) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the growth index. Total revenue increased 79.48% from $95.5 to $171.4, and EBIT increased 35.09% from -$573.9 to -$372.5.
D
Sell
8/19/2019Downgrade
Abattis Bioceuticals Corp. (ATTBF) was downgraded to D- from D on 8/19/2019 due to a substantial decline in the efficiency index, total return index and solvency index. The quick ratio declined from 16.55 to 14.48.
Abattis Bioceuticals Corp. (ATTBF) was downgraded to D- from D on 8/19/2019 due to a substantial decline in the efficiency index, total return index and solvency index. The quick ratio declined from 16.55 to 14.48.
D
Sell
11/30/2018Downgrade
Abattis Bioceuticals Corp. (ATTBF) was downgraded to D from D+ on 11/30/2018 due to a decline in the total return index and volatility index.
Abattis Bioceuticals Corp. (ATTBF) was downgraded to D from D+ on 11/30/2018 due to a decline in the total return index and volatility index.
D
Sell
10/8/2018Upgraded
Abattis Bioceuticals Corp. (ATTBF) was upgraded to D+ from D on 10/8/2018 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.0309 to -$0.0139, and EBIT increased 37.85% from -$8.63M to -$5.36M.
Abattis Bioceuticals Corp. (ATTBF) was upgraded to D+ from D on 10/8/2018 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.0309 to -$0.0139, and EBIT increased 37.85% from -$8.63M to -$5.36M.
D
Sell
6/5/2018Upgraded
Abattis Bioceuticals Corp. (ATTBF) was upgraded to D from D- on 6/5/2018 due to a significant increase in the efficiency index, solvency index and valuation index. Total capital increased 525.96% from $8.6M to $53.82M.
Abattis Bioceuticals Corp. (ATTBF) was upgraded to D from D- on 6/5/2018 due to a significant increase in the efficiency index, solvency index and valuation index. Total capital increased 525.96% from $8.6M to $53.82M.
D
Sell
3/12/2018Downgrade
Abattis Bioceuticals Corp. (ATTBF) was downgraded to D- from D on 3/12/2018 due to a major decline in the total return index and growth index. Operating cash flow declined 498.7% from -$376.3 to -$2.25M, EBIT declined 169.46% from -$1.81M to -$4.88M, and earnings per share declined from -$0.016 to -$0.0222.
Abattis Bioceuticals Corp. (ATTBF) was downgraded to D- from D on 3/12/2018 due to a major decline in the total return index and growth index. Operating cash flow declined 498.7% from -$376.3 to -$2.25M, EBIT declined 169.46% from -$1.81M to -$4.88M, and earnings per share declined from -$0.016 to -$0.0222.
D
Sell
2/2/2018Upgraded
Abattis Bioceuticals Corp. (ATTBF) was upgraded to D from D- on 2/2/2018 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 1.34 to 1.49.
Abattis Bioceuticals Corp. (ATTBF) was upgraded to D from D- on 2/2/2018 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 1.34 to 1.49.
D
Sell
10/4/2017Upgraded
Abattis Bioceuticals Corp. (ATTBF) was upgraded to D- from E+ on 10/4/2017 due to an increase in the volatility index, solvency index and total return index. Debt to equity declined from 0.02 to 0, and the quick ratio increased from 0.71 to 1.34.
Abattis Bioceuticals Corp. (ATTBF) was upgraded to D- from E+ on 10/4/2017 due to an increase in the volatility index, solvency index and total return index. Debt to equity declined from 0.02 to 0, and the quick ratio increased from 0.71 to 1.34.
E
Sell
8/16/2017Downgrade
Abattis Bioceuticals Corp. (ATTBF) was downgraded to E+ from D- on 8/16/2017 due to a noticeable decline in the total return index and volatility index.
Abattis Bioceuticals Corp. (ATTBF) was downgraded to E+ from D- on 8/16/2017 due to a noticeable decline in the total return index and volatility index.
D
Sell
6/1/2017Downgrade
Abattis Bioceuticals Corp. (ATTBF) was downgraded to D- from D on 6/1/2017 due to a large decline in the total return index.
Abattis Bioceuticals Corp. (ATTBF) was downgraded to D- from D on 6/1/2017 due to a large decline in the total return index.
D
Sell
2/24/2017Upgraded
Abattis Bioceuticals Corp. (ATTBF) was upgraded to D from D- on 2/24/2017 due to a significant increase in the total return index and volatility index.
Abattis Bioceuticals Corp. (ATTBF) was upgraded to D from D- on 2/24/2017 due to a significant increase in the total return index and volatility index.
D
Sell
3/11/2016Downgrade
Abattis Bioceuticals Corp. (ATTBF) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index. Total revenue declined 100% from $12.1 to $0.
Abattis Bioceuticals Corp. (ATTBF) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index. Total revenue declined 100% from $12.1 to $0.
D
Sell
4/11/2014Upgraded
Abattis Bioceuticals Corp. (ATTBF) was upgraded to D from D- on 4/11/2014 due to an increase in the valuation index and total return index.
Abattis Bioceuticals Corp. (ATTBF) was upgraded to D from D- on 4/11/2014 due to an increase in the valuation index and total return index.
D
Sell
3/24/2014Downgrade
Abattis Bioceuticals Corp. (ATTBF) was downgraded to D- from D on 3/24/2014 due to a noticeable decline in the valuation index.
Abattis Bioceuticals Corp. (ATTBF) was downgraded to D- from D on 3/24/2014 due to a noticeable decline in the valuation index.
OTC PK
04/25/2024 11:49AM Eastern
Quotes delayed
